The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks slide on surging virus cases, stimulus doubts; dollar rises

Mon, 26th Oct 2020 15:46

* Market recovery may take longer than hoped - OPEC
official

* Graphic: 2020 asset performance http://tmsnrt.rs/2yaDPgn
(Updates prices, changes comment, dateline; previous
LONDON/SYDNEY)

By Rodrigo Campos

NEW YORK, Oct 26 (Reuters) - Shares fell across the globe on
Monday as surging coronavirus cases in Europe and the United
States clouded the world economic outlook, giving the dollar a
safe-haven boost.

The United States, Russia and France set new daily records
for coronavirus infections as a resurgence of the virus swelled
across parts of the Northern Hemisphere, forcing some countries
to impose new curbs.

The spreading pandemic, along with no clear progress on a
U.S. stimulus package and caution ahead of the Nov. 3 U.S.
presidential election dragged the MSCI world equity index
down.

"The market is vulnerable to these 'bad headlines,' because
investors are generally so optimistic right now," said Willie
Delwiche, investment strategist at Baird in Milwaukee.

MSCI's gauge of stocks globally hit a record high in
September and brushed against it earlier this month.

"The market is set up for disappointment at this point,"
Delwiche said.

The Dow Jones Industrial Average fell 712.83 points,
or 2.52%, to 27,622.74, the S&P 500 lost 73.34 points, or
2.12%, to 3,392.05 and the Nasdaq Composite dropped
189.90 points, or 1.64%, to 11,358.38.

The pan-European STOXX 600 index lost 1.72% and
MSCI's gauge of stocks across the globe shed
1.69%.

Emerging market stocks lost 0.66%. MSCI's broadest index of
Asia-Pacific shares outside Japan closed 0.41%
lower, while Japan's Nikkei fell 0.09%.

Europe became the second region after Latin America to
surpass 250,000 deaths on Saturday, according to a Reuters
tally, as many European countries reported their highest number
of COVID-19 cases in a single day.

Sentiment was also hit by a survey showing German business
morale fell in October for the first time in six months.

Reports of progress in a COVID-19 vaccine being developed by
the University of Oxford and manufactured by drugmaker
AstraZeneca Plc helped limit some of the market
sell-off, analysts said.

As markets increasingly price in the likelihood of a
Democratic president and Congress which would likely result in a
rise in government spending and borrowing, U.S. 10-year Treasury
yields hit their highest since early June last week at 0.872%
.

"We have raised the probability of a Democratic sweep,
already our base case, from 40% to just over 50% and have
increased our expectation of (Democratic presidential
candidate)Biden to win from 65% to 75%," NatWest Markets
analysts said. "We see steeper U.S. yield curves and a weaker
USD as likely to prevail in our base case."

Benchmark 10-year notes last rose 13/32 in price
to yield 0.7977%, from 0.841% late on Friday.

BlackRock Inc, the world's largest asset manager, on
Monday downgraded U.S. Treasuries and upgraded their
inflation-linked peers ahead of the U.S. election.

Despite encouraging news about a COVID-19 vaccine out of
Oxford, surging coronavirus cases sent investors to the safety
of the dollar.

"Skittish investors are scooping up the greenback as virus
cases accelerate around the world, stimulus talks in Washington
remain in limbo, and trepidation is on the rise ahead of
America's presidential election," said Joe Manimbo, senior
market analyst, at Western Union Business Solutions in
Washington.

The dollar index rose 0.316%, with the euro
down 0.43% to $1.1808.

The Japanese yen weakened 0.15% versus the greenback at
104.90 per dollar, while sterling was last trading at
$1.3007, down 0.25% on the day.

In commodity markets, spot gold added 0.2% to
$1,904.46 an ounce. Silver fell 1.02% to $24.33.

Oil prices extended last week's losses. OPEC's secretary
general said an oil market recovery may take longer than hoped
as coronavirus inflections rise around the world, and OPEC and
its allies would "stay the course" in balancing the market.

U.S. crude was down 3.64% at $38.40 per barrel and
Brent was at $40.37, down 3.35% on the day.

(Reporting by Rodrigo Campos; additional reporting by Lewis
Krauskopf and Gertrude Chavez-Dreyfuss in New York, Ross Gerber
in Boston, Tom Arnold in London and Wayne Cole in Sydney;
Editing by Susan Fenton)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.